Drugs Containing Excipient (Inactive Ingredient) GELATIN

Branded drugs containing GELATIN excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	STRATTERA	atomoxetine hydrochloride	0002-3227	GELATIN
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3230	GELATIN
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3231	GELATIN
Eli Lilly and Company	CYMBALTA	duloxetine hydrochloride	0002-3235	GELATIN
Eli Lilly and Company	RETEVMO	selpercatinib	0002-3977	GELATIN	2038-04-10

Generic drugs containing GELATIN excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	atomoxetine hydrochloride	0002-3227	GELATIN
Eli Lilly and Company	olanzapine and fluoxetine hydrochloride	0002-3230	GELATIN
Eli Lilly and Company	olanzapine and fluoxetine hydrochloride	0002-3231	GELATIN
Eli Lilly and Company	duloxetine hydrochloride	0002-3235	GELATIN
Eli Lilly and Company	selpercatinib	0002-3977	GELATIN

Gelatin Pharmaceutical Excipient Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 19, 2026

Gelatin is a mature, globally traded pharmaceutical excipient used mainly in hard and soft capsules, hemostatic products, coatings, binders, stabilizers, and selected drug-delivery systems. The market is driven by capsule demand, biopharmaceutical formulation activity, consumer acceptance of animal-derived materials, and supply-chain pricing for collagen raw materials.

Pharmaceutical gelatin has limited standalone patent protection. The commercial barriers are primarily regulatory qualification, animal-origin controls, validated manufacturing, customer approvals, and supply reliability. Market growth is likely to remain moderate in volume terms, while value growth will depend on raw-material inflation, energy costs, geographic sourcing, and migration toward fish, bovine, and non-animal alternatives.

What is pharmaceutical gelatin and how is it used?

Pharmaceutical gelatin is a purified protein produced by controlled hydrolysis of collagen derived mainly from porcine skin, bovine hide or bone, and fish. It is supplied in different grades based on bloom strength, viscosity, particle size, moisture, ash, microbiological quality, and processing characteristics.

Application	Function of gelatin	Commercial relevance
Hard capsules	Capsule-shell polymer	Largest pharmaceutical use
Softgels	Elastic shell former and plasticized film	High-volume use in vitamins, supplements, and pharmaceuticals
Hemostatic products	Absorbable matrix	Higher-value, clinically sensitive application
Tablets	Binder, coating, or film-forming agent	Smaller than capsule use
Microencapsulation	Wall material	Used in controlled-release and taste-masking systems
Vaccines and biologics	Stabilizer in selected formulations	Product-specific and highly qualified
Drug delivery	Hydrogel, scaffold, or particulate matrix	Specialized development market

The excipient is listed in the FDA Inactive Ingredient Database for multiple dosage forms and routes. Its use remains dependent on the specific grade, concentration, route of administration, and finished-product formulation rather than on a universal approval for every pharmaceutical application.[1]

How large is the pharmaceutical gelatin market?

Published market estimates vary because some reports measure all gelatin, while others include pharmaceutical capsules, nutraceuticals, medical devices, and technical gelatin. The pharmaceutical-excipient segment is therefore smaller than the global gelatin market reported by commercial research firms.

Market scope	Typical reported position
Total gelatin	Includes food, nutraceutical, pharmaceutical, photographic, and technical applications
Pharmaceutical gelatin	Includes excipient-grade gelatin and gelatin used in pharmaceutical manufacturing
Capsule-shell gelatin	Focuses on hard and soft capsule production
Medical gelatin	Includes hemostats and regenerative products, which may have different economics

Commercial market reports generally place the global gelatin market in the multibillion-dollar range and project mid-single-digit annual growth through the early 2030s. These figures should not be treated as pharmaceutical-excipient revenue because food and nutraceutical applications account for a substantial share.[2][3]

A reasonable operating view is:

• Pharmaceutical gelatin volume growth: low- to mid-single digits annually.
• Pharmaceutical capsule demand: linked to oral solid-dose growth and contract manufacturing.
• Value growth: potentially higher than volume growth during periods of collagen, energy, freight, and compliance-cost inflation.
• Margin profile: strongest for validated specialty grades, medical gelatin, and customer-specific formulations.
• Commodity exposure: highest for standard capsule-shell gelatin and large-volume hard-capsule supply.

What is driving gelatin excipient demand?

Capsule manufacturing remains the core demand engine

Gelatin remains the dominant material for conventional hard and soft capsules. It provides established mechanical performance, rapid processing, broad formulation compatibility, and extensive regulatory history. Capsule manufacturers also benefit from existing equipment and process controls optimized for gelatin shells.

Demand is supported by:

1. Growth in generic oral medicines.
2. Continued use of capsules in clinical development and commercial products.
3. Expansion of nutraceutical and supplement manufacturing.
4. Outsourcing to contract development and manufacturing organizations.
5. Demand for modified-release, liquid-filled, and specialty capsules.

Hydroxypropyl methylcellulose and other plant-based capsule materials are the principal competitive substitutes. Their adoption is strongest where customers require vegetarian positioning, non-animal sourcing, lower cross-linking risk, or compatibility with specific moisture-sensitive formulations.

Biologics and advanced delivery systems create selective growth

Gelatin is not a broad substitute for synthetic or recombinant excipients in biologics. Its use depends on product-specific stability data, immunogenicity assessment, source controls, and regulatory precedent. The most defensible growth opportunities are specialized matrices, wound care, absorbable hemostats, tissue engineering, and delivery systems rather than routine biologic formulation.

Geographic demand is concentrated in Asia and North America

Asia-Pacific is the largest manufacturing region for gelatin, capsules, and pharmaceutical contract production. China and India are important sources of demand and supply, while Japan has established gelatin and capsule manufacturers. North America and Europe remain high-value markets because customers require extensive documentation, traceability, pharmacopoeial compliance, and change-control discipline.

Which companies supply pharmaceutical gelatin?

The leading global suppliers include Rousselot, PB Leiner, GELITA, Nitta Gelatin, Geltech, and regional producers serving capsule and medical-device manufacturers. Rousselot and PB Leiner are part of Darling Ingredients’ collagen and gelatin operations. GELITA is privately held and is one of the largest global gelatin and collagen suppliers. Nitta Gelatin has operations across Japan, North America, India, and other markets.

Company	Position in the value chain	Relevant strength
Rousselot	Gelatin and collagen supplier	Global scale and pharmaceutical-grade materials
PB Leiner	Gelatin and collagen supplier	Pharmaceutical, nutraceutical, and technical grades
GELITA	Gelatin and collagen supplier	Broad global manufacturing and specialty gelatin
Nitta Gelatin	Gelatin and collagen supplier	Pharmaceutical, capsule, and medical applications
Lonza and Capsugel-related manufacturers	Capsule and drug-delivery manufacturing	Downstream conversion and customer qualification
Regional capsule producers	Shell manufacturing	Local supply and lower-cost production

The market is concentrated at the high-quality end because pharmaceutical customers tend to qualify multiple suppliers only after lengthy technical and regulatory reviews. Supplier replacement can require comparability work, stability studies, process validation, and regulatory submissions.

How strong is the patent estate for pharmaceutical gelatin?

Gelatin itself has little meaningful composition-of-matter patent protection. It is an established material derived from collagen, and the underlying substance is not a new chemical entity. Most relevant intellectual-property protection falls into four categories:

• Manufacturing processes that control hydrolysis, purity, viscosity, bloom strength, or molecular-weight distribution.
• Cross-linked or chemically modified gelatin systems.
• Gelatin-based drug-delivery matrices, nanoparticles, hydrogels, and implants.
• Capsule-shell compositions combining gelatin with plasticizers, colors, preservatives, or active ingredients.

Patent strength is therefore application-specific. A standard gelatin excipient grade usually has weak standalone patent barriers, while a proprietary gelatin hydrogel, medical implant, or controlled-release system can have stronger composition, process, and use claims.

What patents protect gelatin formulations?

The most commercially relevant patent claims generally cover:

• Cross-linking chemistry that modifies dissolution or release.
• Gelatin-polysaccharide or gelatin-polymer blends.
• Gelatin nanoparticles and microparticles.
• Injectable or implantable gelatin scaffolds.
• Capsule compositions with selected plasticizer and moisture ranges.
• Manufacturing conditions that create a defined molecular-weight profile.
• Use of gelatin in wound healing, tissue regeneration, or hemostasis.

A patent search should separate the excipient from the finished drug product. A patent claiming a gelatin-based delivery matrix does not necessarily prevent use of ordinary pharmaceutical gelatin in a capsule. Conversely, a finished pharmaceutical patent may list gelatin as an excipient without creating a patent right over gelatin supply.

When does gelatin lose exclusivity?

Gelatin has no single patent-expiration date because it is a material class rather than a single branded medicine. Traditional pharmaceutical gelatin is effectively off-patent. Exclusivity can still exist around a particular supplier grade, manufacturing process, delivery system, or medical product.

IP or regulatory asset	Typical exclusivity position
Conventional gelatin material	No meaningful composition exclusivity
Pharmacopoeial grade	Protected by quality standards, not exclusivity
Supplier process	Potentially protected by patents and trade secrets
Gelatin capsule shell	Usually mature technology; formulation patents may apply
Gelatin-based medical device	Product-specific patent and regulatory protection
Gelatin drug-delivery system	Patent term normally tied to filing date and jurisdiction

Trade secrets may be more important than patents for controlling hydrolysis conditions, filtration, demineralization, drying, and batch consistency. Those protections do not appear in public patent databases and can persist as long as the information remains confidential.

What is the FDA regulatory status of gelatin?

Gelatin is an established excipient, but regulatory acceptance depends on source, grade, route, and manufacturing controls. FDA review typically focuses on:

• Identity and purity.
• Microbiological control.
• Residual processing chemicals.
• Heavy metals and other impurities.
• Bovine spongiform encephalopathy and transmissible spongiform encephalopathy controls.
• Viral and adventitious-agent controls.
• Traceability to animal origin.
• Allergen and labeling considerations.
• Compliance with relevant USP-NF requirements.

The USP-NF includes a Gelatin monograph, and the European Pharmacopoeia includes a gelatin monograph. Manufacturers also rely on excipient certificates, supplier qualification files, audit reports, and change-control agreements.[4][5]

FDA does not generally approve excipients through a standalone application comparable to a new drug application. Drug sponsors qualify gelatin within the finished product and must demonstrate that the excipient is suitable for the intended use.

What is the Orange Book status of gelatin?

Gelatin itself has no Orange Book listing because the Orange Book identifies approved drug products and patent or exclusivity information associated with those products, not standalone excipients.[6]

Gelatin can appear in an approved drug’s inactive-ingredient composition. Any patent protection would normally attach to the finished drug, formulation, delivery system, or method of use. It would not automatically create Orange Book-listed protection over the gelatin molecule or generic gelatin supply.

Are there Paragraph IV challenges involving gelatin?

Paragraph IV litigation generally targets patents listed for an approved drug product. It does not normally target gelatin as an excipient. A generic applicant could challenge a listed patent covering a capsule formulation, controlled-release system, or method of use in which gelatin is an ingredient, but the dispute would concern the drug product’s patent claims.

For gelatin suppliers, the more important legal risks are:

• Patent claims directed to proprietary capsule shells.
• Process patents for specialty gelatin grades.
• Trade-secret disputes over production methods.
• Contract disputes involving supply qualification and change control.
• Product-liability claims tied to contamination or animal-origin controls.

There is no broad Paragraph IV exclusivity framework for conventional pharmaceutical gelatin.

What formulation and manufacturing barriers protect gelatin suppliers?

The strongest barriers are operational rather than patent-based.

Raw-material sourcing

Gelatin depends on collagen-rich animal inputs. Supply is affected by livestock volumes, slaughterhouse economics, disease controls, religious requirements, and competition from food and nutraceutical markets.

Quality consistency

Pharmaceutical customers require consistent bloom strength, viscosity, particle size, moisture, ash, microbial limits, and dissolution behavior. A supplier may need to maintain multiple source streams and manufacturing sites to meet customer specifications.

Animal-origin compliance

Bovine, porcine, and fish gelatin have different acceptance profiles. Bovine materials may require TSE controls and regional sourcing documentation. Porcine materials may be excluded by certain customers or markets. Fish gelatin can address some religious or dietary requirements but may have different gel strength, odor, thermal behavior, and supply economics.

Customer switching costs

Capsule and finished-dose manufacturers validate gelatin against equipment, shell performance, fill compatibility, dissolution, and stability. A supplier change can trigger technical comparability work and regulatory notification. This creates retention even when the material itself is not patent protected.

How does gelatin compare with HPMC capsules?

Attribute	Gelatin	HPMC
Source	Animal collagen	Plant-derived cellulose
Cost position	Usually competitive	Often higher
Regulatory history	Extensive	Extensive and expanding
Vegetarian suitability	No	Yes
Moisture behavior	Can interact with moisture-sensitive fills	Often preferred for some sensitive products
Cross-linking risk	Relevant in selected formulations	Generally lower
Supply base	Mature and globally established	Growing, with fewer large-scale suppliers
Consumer acceptance	Strong but source-dependent	Strong where non-animal positioning matters

Gelatin is likely to retain the majority of conventional capsule volume because of cost, installed capacity, and process familiarity. HPMC should continue taking share in vegetarian, clean-label, moisture-sensitive, and specialized delivery applications.

What financial trajectory should investors expect?

The financial trajectory is more stable than that of a patented pharmaceutical but more exposed to input costs and industrial utilization. Gelatin suppliers do not receive exclusivity pricing comparable to branded drug manufacturers. Their earnings depend on volume, product mix, procurement, capacity utilization, pricing discipline, and by-product economics.

Base-case trajectory

The base case is moderate revenue growth with periodic margin volatility:

• Volume expands with capsule and pharmaceutical manufacturing demand.
• Standard gelatin pricing remains competitive.
• Specialty pharmaceutical and medical grades grow faster than commodity grades.
• Input-cost inflation is passed through with a lag.
• Capacity additions in Asia pressure standard-grade pricing.
• Regulatory and quality requirements support premium pricing for qualified suppliers.

Downside factors

• Substitution by HPMC and other non-animal capsule materials.
• Reduced animal raw-material availability.
• Disease outbreaks or regional sourcing restrictions.
• Energy and freight inflation.
• Customer consolidation and purchasing pressure.
• Excess capacity in standard gelatin.
• Public concern over animal origin or supply traceability.

Upside factors

• Growth in softgel pharmaceuticals and supplements.
• Expansion of generic manufacturing in Asia.
• Greater use of gelatin in hemostats and medical devices.
• Premium demand for fish and documented bovine grades.
• Higher outsourcing by drug developers.
• Increased demand for gelatin-based delivery systems.

Public-company disclosures provide limited segment transparency. Darling Ingredients reports collagen and gelatin within broader business segments, while GELITA is privately held and does not publish a full public pharmaceutical-gelatin income statement.[7][8] As a result, supplier-level pharmaceutical gelatin revenue, margins, and market share are not directly comparable.

What generic launch risks exist for gelatin-containing products?

Generic launch risk depends on the drug product, not on gelatin alone. A generic capsule product may face:

• Listed formulation patents.
• Method-of-use patents.
• Controlled-release or enteric-release claims.
• Capsule-shell performance requirements.
• Demonstration of bioequivalence where shell composition affects release.
• Supplier qualification and change-control requirements.
• Animal-origin restrictions in target markets.

For an immediate-release product using conventional gelatin, the excipient is usually a low patent-risk element. For a modified-release, softgel, or gelatin-based delivery product, the formulation and manufacturing claims can materially delay entry.

What licensing deals affect the gelatin market?

Licensing activity is more common in downstream drug delivery, medical devices, recombinant collagen, and capsule technology than in bulk gelatin supply. Standard pharmaceutical gelatin is typically sold under supply, quality, and technical-service agreements rather than classic royalty-bearing licenses.

Commercial agreements may include:

• Dual-source qualification.
• Territory-specific distribution.
• Long-term capacity reservations.
• Minimum purchase commitments.
• Customer-specific specifications.
• Joint development of gelatin matrices or medical products.
• Technology licenses for capsule and delivery platforms.

Key Takeaways

• Gelatin is a mature pharmaceutical excipient with its largest use in hard and soft capsule shells.
• The broader gelatin market is multibillion-dollar, but pharmaceutical-excipient estimates are materially smaller and difficult to isolate.
• Volume growth should remain low to mid-single digit, with value growth influenced by raw-material and manufacturing costs.
• Conventional gelatin has little meaningful composition-of-matter patent protection.
• Process patents, trade secrets, specialty grades, and gelatin-based delivery systems create the strongest defensible positions.
• FDA and pharmacopoeial compliance, animal-origin controls, and customer qualification are major commercial barriers.
• Gelatin competes primarily with HPMC and other non-animal capsule materials.
• Orange Book and Paragraph IV issues generally attach to finished drug products, not gelatin itself.
• Rousselot, PB Leiner, GELITA, and Nitta Gelatin are among the key global suppliers.
• Specialty pharmaceutical, hemostatic, and medical-device grades have better margin potential than standard commodity gelatin.

FAQs About Pharmaceutical Gelatin

Is gelatin a high-value pharmaceutical excipient?

Standard capsule gelatin is a relatively mature, price-competitive excipient. High-purity medical gelatin, specialty delivery grades, and validated customer-specific products can command higher margins.

Can pharmaceutical gelatin be replaced by HPMC?

Yes. HPMC is a major substitute, especially for vegetarian capsules, moisture-sensitive formulations, and products with non-animal sourcing requirements. Replacement requires formulation, process, dissolution, and stability evaluation.

Does gelatin require a Drug Master File?

A supplier may maintain a Type IV Drug Master File or equivalent technical package, but FDA does not require every excipient to have a DMF. The drug sponsor remains responsible for qualifying the excipient in the finished product.

Is bovine gelatin more commercially attractive than porcine gelatin?

Neither is universally superior. Bovine gelatin may be preferred for certain religious, geographic, or customer requirements, while porcine gelatin often has strong processing performance and established supply. Regulatory documentation and customer acceptance determine commercial value.

Are gelatin patents enforceable against generic capsule manufacturers?

Only if a live patent claims the relevant capsule composition, manufacturing process, drug formulation, delivery system, or method of use. A patent on a specific gelatin-based product does not automatically cover conventional pharmaceutical gelatin.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. Grand View Research. (2024). Gelatin market size, share and trends analysis report. https://www.grandviewresearch.com/industry-analysis/gelatin-market
3. Fortune Business Insights. (2024). Gelatin market size, share and industry analysis. https://www.fortunebusinessinsights.com/gelatin-market-102037
4. United States Pharmacopeial Convention. (2024). USP-NF: Gelatin monograph. https://www.usp.org
5. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Gelatin monograph. https://www.edqm.eu
6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
7. Darling Ingredients Inc. (2024). Annual report 2023. https://ir.darlingii.com
8. GELITA AG. (n.d.). Pharmaceutical gelatin and collagen solutions. https://www.gelita.com